Norbel Baby (6844) reported revenue of NT$315.5 million for Oct 2026, +1.1% year on year and +2.0% from the previous month. Revenue for Jan–Oct 2026 was NT$3.14 billion (-0.4% year on year).
Year-on-year revenue growth: 3 months in a row. →
In Oct 2026, it ranked No. 32 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$315.5 million | +1.1% | +2.0% |
| Sep 2026 | NT$309.2 million | +4.1% | -6.9% |
| Aug 2026 | NT$332 million | +0.2% | +7.8% |
| Jul 2026 | NT$307.9 million | +0.0% | +12.4% |
| Jun 2026 | NT$274 million | -1.9% | -11.5% |
| May 2026 | NT$309.7 million | +0.1% | +13.4% |
| Apr 2026 | NT$273.2 million | -0.1% | -3.6% |
| Mar 2026 | NT$283.4 million | +0.5% | -0.4% |
| Feb 2026 | NT$284.5 million | +2.6% | +1.3% |
| Jan 2026 | NT$280.7 million | -9.9% | -7.0% |
| Dec 2025 | NT$301.9 million | +0.3% | +7.5% |
| Nov 2025 | NT$280.8 million | +0.7% | -10.0% |
| Oct 2025 | NT$311.9 million | +13.1% | +5.0% |
| Sep 2025 | NT$297.1 million | +6.6% | -10.3% |
| Aug 2025 | NT$331.3 million | +15.1% | +7.6% |
| Jul 2025 | NT$308 million | +10.3% | +10.3% |
| Jun 2025 | NT$279.3 million | +0.8% | -9.7% |
| May 2025 | NT$309.2 million | +0.9% | +13.1% |
| Apr 2025 | NT$273.5 million | +0.6% | -3.0% |
| Mar 2025 | NT$281.9 million | +3.7% | +1.7% |
| Feb 2025 | NT$277.3 million | -4.8% | -11.0% |
| Jan 2025 | NT$311.5 million | +11.4% | +3.5% |
| Dec 2024 | NT$301 million | +0.9% | +8.0% |
| Nov 2024 | NT$278.7 million | +2.5% | +1.1% |
| Oct 2024 | NT$275.8 million | -4.8% | -1.0% |
Jan–Oct 2026 cumulative: NT$3.14 billion (-0.4% YoY)
Other Biotech & Medical companies
Compare with peers: Norbel Baby vs PEC / Norbel Baby vs Lotus Pharm / Norbel Baby vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
115/7/1取得合躍60%股權,屬共同控制下組織重整,視為自始取得,故重編去年比較期單月及累計營收數。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16